TAG-72 Antibody (0.N.561): sc-59710

TAG-72 Antibody (0.N.561) is a mouse monoclonal IgG1 antibody that detects tumor-associated glycoprotein 72 (TAG-72) in mouse, rat, human, and bovine samples through applications such as immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). TAG-72 is a high molecular weight glycoprotein predominantly localized to the cytoplasm and cell membrane of malignant cells, playing a crucial role in tumor biology as a marker for various cancers. TAG-72 expression is notably high in approximately 80% of colorectal carcinomas, while being rarely found in normal epithelial tissues and benign conditions, making TAG-72 a valuable target for cancer diagnostics and therapeutics. TAG-72 is significantly expressed in low-grade mucoepidermoid carcinomas and is associated with several gynecologic malignancies, including common epithelial ovarian and endometrial carcinomas. In human prostatic adenocarcinomas, TAG-72 expression has been shown to negatively correlate with the Gleason grade of differentiation, indicating TAG-72′s potential as a prognostic marker. TAG-72 is expressed in the majority of gastric, esophageal, pancreatic, and non-small cell lung carcinomas, highlighting TAG-72′s broad relevance in oncology. TAG-72′s ability to aid in the purification of primary ovarian cancer cells from patient ascites further underscores TAG-72′s importance in cancer research and treatment strategies. Anti-TAG-72 antibody (0.N.561) is an essential tool for researchers aiming to explore TAG-72′s role in various malignancies and potential as a therapeutic target.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

TAG-72 Antibody (0.N.561) References:

1. Distribution of tumor-associated glycoprotein-72 (TAG-72) expression throughout the normal female reproductive tract.  |  Osteen, KG., et al. 1992. Int J Gynecol Pathol. 11: 216-20. PMID: 1399229
2. Expression of CEA, Tag-72, and Lewis-Y antigen in primary and metastatic lesions of ovarian carcinoma.  |  Chhieng, DC., et al. 2003. Hum Pathol. 34: 1016-21. PMID: 14608535
3. A new TAG-72 cancer marker peptide identified by phage display.  |  Chen, L., et al. 2008. Cancer Lett. 272: 122-32. PMID: 18723274
4. Tumor-associated glycoprotein (TAG-72) expression in ulcerative colitis.  |  Thor, A., et al. 1989. Int J Cancer. 43: 810-5. PMID: 2654025
5. A 3E8.scFv.Cys-IR800 Conjugate Targeting TAG-72 in an Orthotopic Colorectal Cancer Model.  |  Gong, L., et al. 2018. Mol Imaging Biol. 20: 47-54. PMID: 28643153
6. Linker engineering in anti-TAG-72 antibody fragments optimizes biophysical properties, serum half-life, and high-specificity tumor imaging.  |  Long, NE., et al. 2018. J Biol Chem. 293: 9030-9040. PMID: 29669811
7. Improved targeting of an anti-TAG-72 antibody drug conjugate for the treatment of ovarian cancer.  |  Minnix, M., et al. 2020. Cancer Med. 9: 4756-4767. PMID: 32368864
8. Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3.  |  Thor, A., et al. 1986. J Natl Cancer Inst. 76: 995-1006. PMID: 3520078
9. Expression of CA 72-4 (TAG-72) in the fluid contents of pancreatic cysts. A new marker to distinguish malignant pancreatic cystic tumors from benign neoplasms and pseudocysts.  |  Alles, AJ., et al. 1994. Ann Surg. 219: 131-4. PMID: 8129483
10. A model for others: a strategy for improving diagnosis and therapy of human malignancies using monoclonal antibodies targeting TAG-72 oncofetal antigen.  |  Larson, SM. 1993. Cancer Invest. 11: 235-8. PMID: 8462025

The preferred TAG-72 antibody is TAG-72 Antibody (CC49): sc-20043.